P-0091 Prediction of Hcc in Cirrhotic Patients with an Arterially Enhancing Liver Mass

Merkel cell carcinoma (MCC) is a rare primary neuroendocrine carcinoma of the skin, with very aggressive behavior. Etiological factors contributing to MCC development, include exposure to UV radiation, infection with Merkel cell polyomavirus (MCPyV) and chronic immunosuppression. It is commonly found in regions of the body that are exposed to sun -55% of cases are located in the head and neck. The 5 years survival rate for metastatic disease is approximately 25%. The estimated mortality rate for MCC is between 33% and 46%. Therapeutic options for MCC depends on disease characteristics (stage of disease at presentation, location of the tumor, regional lymph node involvement, comorbidities and performance status of the patient) and it includes multimodal treatments like surgery, chemotherapy and emerging immunotherapeutic treatments with early promising results. Our clinic experience is very limited with this type of malignancy, only three cases were diagnosed and treated in our department, but with encouraging results regarding the newest immunotherapeutic options, with good quality of life and results similar with the data from the literature.

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Merkel Cell Carcinoma - A Rare Form of Skin Cancer with New Therapeutic Options

Stănculeanu¹,

Toma²,

Vasile³

et al. 2019

Differential Diagnosis in Esophageal Cancer. Review on literature

Popa¹,

Badiu²,

Andronache³

et al. 2019

Esophageal cancer represents a neoplasm that is thought to have both an increased incidence and prevalence in the following years. Although much progress has been made in the detection and the early treatment of esophageal cancer, the prognosis is still limited, and mortality remains very high. The most common histological types of esophageal cancer are squamous cell carcinoma, and, respectively, adenocarcinoma. Lately, there has been an accelerated increase in the incidence of adenocarcinoma, in the context of increased prevalence of gastro-esophageal reflux disease and obesity, but also of the current alimentary diet, especially in developed countries. The esophagus has its anatomical features. Moreover, it is located topographicallyin a complex cervico-thoraco-abdominal area, unique for a viscus. From the clinical point of view, the onset of symptoms of esophageal cancer is insidious. For these reasons, special attention should be pain in the early detection and differentiation of this neoplasm from other pathologies. These pathologies are very varied and may comprise other esophageal diseases, neighborhood pathologies such as cervical, thoracic, abdominal, systemic pathologies (immunologic, infectious) or other pathologies such as the oro-maxillo-facial, oculo-orbital, vascular, muscular, and cutaneous ones. Keywords: esophagus, cancer, differential diagnosis

Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer

Gheorghe¹,

Zob²,

Stanculeanu³

2020

Even with the decreasing incidence of colorectal cancer (CRC), data showing that the rate of incidence of CRC is declining with 2.9% every year starting with 2005 until 2014, CRC remains one of the most frequent neoplasia all over the world. Almost a quarter of patients with CRC present with stage IV disease at diagnosis and nearly 30% of patients with localized disease will progress within 5 years. Our study included 129 patients with metastatic CRC that received chemotherapy � bevacizumab, from January 2017 until December 2018. Patients received fluropirimidine-based chemotherapy plus or minus bevacizumab. No significant differences was registered between groups with respects of age, sex, tumor localization, chemotherapy regimen used. Also no significant difference was found in our groups regarding risk factors for bleeding and medical history. No remarkable differences were registered between the two groups regarding common adverse reactions to chemotherapy, with the exception of physical asthenia which was found in a greater proportion of patients that received bevacizumab in combination with chemotherapy. In our study most frequent adverse events related to bevacizumab were grade 1 or 2, only few adverse events were grade 3 or 4 and lead to discontinuation of bevacizumab treatment, and these were mainly thromboembolic events and bleeding.